December 14, 2022, 12:00 PM - 2:00 PM ET
Overview
The treatment of follicular lymphoma (FL) is continually evolving with the introduction of new targeted therapies, cellular therapies, and immunoradiotherapy. These advances present new opportunities to tailor treatment approaches for patients with FL based on disease-related and patient-related factors.
During this live webcast, the panel of expert faculty will review recent updates in the management of FL and discuss and debate how to incorporate recent advances to optimize the treatment approach throughout the disease continuum through a series of case studies. The panel will also review how to identify patients who may be candidates for new treatment approaches and review emerging evidence that could affect treatment paradigms in the future.
Target Audience
This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals who treat patients with follicular lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistance, and other health care professionals interested in the treatment of patients with follicular lymphoma are also invited to participate.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Explain diagnostic criteria, prognostic evaluation, best practices, and the use of biomarkers guiding decision-making in FL
- Synthesize safety data with current and emerging therapeutics in the context of sequencing in FL
- Compare guideline recommendations in consideration of practice-changing advances in the management of FL
- Determine ongoing studies and recent trial results impacting evolving treatment paradigms in FL
Follicular Lymphoma Workshop: Forging Patient-Centric Plans With Targeted Therapies Across Lines of Care December 14, 2022 Virtual |
|
Eastern Time Zone |
|
12:00 pm |
Welcome and Introductions |
12:10 pm |
Defining the Diagnostic and Prognostic Features of FL for Selection of Risk-Adapted Frontline Therapy |
12:25 pm |
Workshop 1: Applying Pathophysiology and Diagnosis to Practice |
12:40 pm |
Optimizing Second-Line and Later-Line Treatment Options in FL via Integration of Key Data Sets and Evidence-Based Guidelines |
12:55 pm |
Workshop 2: Creating a Plan in FL Beyond the Frontline Setting |
1:10 pm |
CAR T-Cell Therapy: Right Patient, Right Time in Relapsed/Refractory FL |
1:25 pm |
Workshop 3: Identifying Candidates for CAR T-Cell Therapy |
1:40 pm |
Audience Q&A |
1:55 pm |
Summary and Conclusions |
Loretta J. Nastoupil, MD
Associate Professor
Deputy Chair
Department Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX
Caron A. Jacobson, MD, MMSc
Assistant Professor of Medicine,
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, MA
Ian W. Flinn, MD, PhD
Director, Lymphoma Research
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN
Jessica Okosun, MB BChir, PhD
Centre for Haemato-Oncology
Barts Cancer Institute
London, United Kingdom
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.